Filtered By:
Drug: Angiomax

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Frequency and predictors of diagnostic coronary angiography and percutaneous coronary intervention related to stroke
CONCLUSIONS: Based on the large national registry, PCI ± DCA is associated with fewer risk factors and lower rate of periprocedural strokes than isolated DCA.PMID:34472076 | DOI:10.33963/KP.a2021.0100
Source: Polish Heart Journal - September 2, 2021 Category: Cardiology Authors: Bart łomiej Staszczak Krzysztof P Malinowski Wojciech Wa ńha Zbigniew Siudak Magdalena J ędrychowska Micha ł Susuł S ławomir Surowiec Szymon Darocha Andrzej Surdacki Marcin Kurzyna Wojciech Wojakowski Jacek Legutko Krzysztof Bartu ś Stanis ław Bar Source Type: research

BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ
In the BRAVO-3 trial of patients who had transfemoral TAVR with procedural bivalirudin or heparin, patients with new-onset AF had a much greater stroke risk; there was also an"incredible" variation in discharge meds.Heartwire from Medscape
Source: Medscape Medical News Headlines - May 12, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research

Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry
Conclusions In patients undergoing primary PCI via transradial access anticoagulated with bivalirudin or heparin, there was no difference in the composite endpoint of death, myocardial infarction, or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 5, 2017 Category: Cardiology Authors: Jovin, I. S., Shah, R. M., Patel, D. B., Rao, S. V., Baklanov, D. V., Moussa, I., Kennedy, K. F., Secemsky, E. A., Yeh, R. W., Kontos, M. C., Vetrovec, G. W. Tags: Coronary Source Type: research

Lessons Learned from Managing Antithrombotic Therapy in Children Supported with Pediatric Ventricular Assist Devices
Stroke, thromboembolism, and bleeding are the most recognized complications associated with pediatric ventricular assist devices (VADs) and the leading cause of death and disability on VAD support. Recently, newer antithrombotic strategies like bivalirudin have emerged that appear to be associated with a reduction in the neurologic event rates, especially for smaller pediatric-specific VADs like the Berlin Heart and PediMag/CentriMag systems where the risk of stroke is the highest. While contemporary antithrombotic therapies have likely contributed to lowering adverse event rates, we speculate that clotting and bleeding ad...
Source: ASAIO Journal - November 1, 2022 Category: Medical Devices Tags: Review Source Type: research

Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting: A Propensity Score Analysis From the NCDR Peripheral Vascular Disease
Conclusions— Bivalirudin was associated with lower rates of hemorrhagic outcomes compared with UFH during the index hospitalization for carotid artery stenting. In-hospital and 30-day ischemic events were similar between the 2 groups. Randomized comparisons of these agents are needed to confirm these findings.
Source: Circulation: Cardiovascular Interventions - April 16, 2013 Category: Cardiology Authors: Wayangankar, S. A., Abu-Fadel, M. S., Aronow, H. D., Kennedy, K. F., Gupta, R., Yeh, R. W., Gray, W. A., Rosenfield, K., Hennebry, T. A. Tags: Heparin, Other anticoagulants, Carotid Stenosis, Angioplasty and Stenting, Transient Ischemic Attacks Peripheral Vascular Disease Source Type: research

Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
Conclusion: In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.
Source: International Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Martial Hamon, Christopher A. Nienaber, Stefano Galli, Kurt Huber, Janusz Lipiecki, Jonathan M. Hill, Nicolas Amabile, Debra Bernstein, Efthymios Deliargyris, Antoine Lafont, Philippe Gabriel Steg Tags: Original Articles Source Type: research

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial. Clinical trial registration information Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta ‐analysis of studies
ConclusionCompared to UFH, Bivalirudin is associated with lower bleeding risk when used during CAS. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - August 15, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Jad Omran, Obai Abdullah, Mazen Abu ‐Fadel, William A Gray, Belal Firwana, Douglas E Drachman, Ehtisham Mahmud, Herebert D Aronow, Christopher J White, Ashraf S Al‐Dadah Tags: Peripheral Vascular Disease Source Type: research

Effectiveness and Safety of Bivalirudin During Percutaneous Coronary Intervention in Acute Coronary Syndrome in the Real World: CARTAGOMAX Study
Abstract: The CARTAGOMAX study assessed the safety and efficacy of bivalirudin during real-world cardiac intervention. This was a single-center prospective study. Patients with acute coronary syndrome undergoing percutaneous coronary intervention were anticoagulated with bivalirudin alone or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. Propensity score matching was performed to control for baseline imbalances and yielded 1168 patients. There was lower incidence of the composite outcome of death from any cause or major bleeding at 30 days (P = 0.005), 6 months (P = 0.005), and 12 months (P = 0.001) of foll...
Source: Journal of Cardiovascular Pharmacology - September 1, 2016 Category: Cardiology Tags: Original Article Source Type: research

Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: pooled analysis from the EUROMAX and HORIZONS-AMI trials
Conclusions In a large group of elderly patients enrolled in the EUROMAX and HORIZONS-AMI trials, bivalirudin was associated with lower 30-day rates of non-CABG major bleeding, subacute ST and NACE, with similar 30-day rates of acute ST and mortality.
Source: American Heart Journal - August 18, 2017 Category: Cardiology Source Type: research

Bivalirudin versus heparin in patients undergoing percutaneous transcatheter aortic valve interventions: A systematic review and meta ‐analysis
ConclusionsIn patient undergoing aortic valve interventions, no difference was seen between the use of bivalirudin and heparin as the procedural anticoagulant agent, except for a significant lower myocardial infarction events when bivalirudin was used. Further large randomized trials are needed to confirm current results.
Source: Journal of Interventional Cardiology - August 21, 2017 Category: Cardiology Authors: Pedro A. Villablanca, Rasha Al ‐Bawardy, Divyanshu Mohananey, Carola Maraboto, Michael Weinreich, Tanush Gupta, David F. Briceno, Harish Ramakrishna Tags: ORIGINAL INVESTIGATION Source Type: research

Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy.
CONCLUSION: Both heparin and bivalirudin were safe and effective antithrombotic agents for patients who underwent orbital atherectomy. A randomized trial is needed to determine the antithrombotic agent of choice for orbital atherectomy. PMID: 29086730 [PubMed - in process]
Source: The Journal of Invasive Cardiology - November 2, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0
Int J Artif Organs. 2021 Jul 12:3913988211032238. doi: 10.1177/03913988211032238. Online ahead of print.ABSTRACTTemporary mechanical circulatory support (tMCS) devices are used for the management of cardiogenic shock. The Impella 5.0 (Abiomed; Danvers, MA) (IMP5) is a commonly used, surgically implanted, tMCS device that requires systemic anticoagulation and purge solution to avoid pump failure. To avoid heparin-induced thrombocytopenia (HIT) from unfractionated heparin (UFH) use, our program has explored the utility of bivalirudin (BIV) for systemic anticoagulation in IMP5. This single center, retrospective study included...
Source: The International Journal of Artificial Organs - July 12, 2021 Category: Transplant Surgery Authors: Carly Fabrizio Marissa N Levito Ryan Rivosecchi Michael Bashline Brittany Slocum Arman Kilic Catalin Toma Holt Murray Raj Ramanan Jeffrey Fowler Gavin W Hickey Edward T Horn Source Type: research